An experimental drug just showed it can help slow Alzheimer's, offering new hope for patients and a major boost to pharma giant Eli Lilly

• An experimental drug for Alzheimer's disease has cleared a big hurdle, moving it closer to approval.
• The pharma giant Eli Lilly said donanemab slowed cognitive decline in people with Alzheimer's.
• The news comes months after the FDA approved an Alzheimer's drug called Leqembi.

After years of stagnation, treatments for Alzheimer's are experiencing a revival.